AstraZeneca Announced Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
UPDATE: Aridis Top-Line Results Of The Phase 3 Double-blinded, Superiority Trial Of Ar-301 Primary Outcome Measures Of Safety And Tolerability Of AR-301 Were Achieved
Primary outcome measures of safety and tolerability of AR-301 were achieved. AR-301 intravenous (IV) infusion was well tolerated. Adverse Events (AEs) and Serious Adverse Events (SAEs) reported over the 28-day study period for the single IV infusion were similar across the active and placebo treatment groups, with no SAEs deemed drug-related.
GeoVax Receives Notice of Allowance For Zika Vaccine Patent
U.S. Patent and Trademark Office issued a Notice of Allowance for Patent Application No. 17/000,768 titled, "Method for Generating a ZIKV Immune Response Utilizing a Recombinant Modified Vaccinia Ankara Vector
Capricor Therapeutics Announces 18-Month Results From Ongoing HOPE-2 Open Label Extension Study Of CAP-1002 In Duchenne Muscular Dystrophy Patients
-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in Skeletal Muscle Function-
-Results Continue to Suggest Potential
Innate Pharma Announces HSR Clearance Regarding Expansion Of Its Collaboration With Sanofi On NK Cell Engagers
Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cell engagers, the licensing agreement between Sanofi and Innate is now effective.
Innate Pharma SA
Aridis Pharmaceuticals Currently Presenting Webinar; ‘New Approaches To Treating Infections In Cystic Fibrosis Patients AR-501 Phase 2 Trial Update’; Shares Spike Lower
https://redchip.zoom.us/webinar/register/WN_WB4K1ES0S1aJzl5ucesN5A
Allogene Therapeutics Announces Publication In Nature Medicine Of Data From Its Phase 1 UNIVERSAL Study Of ALLO-715 For The Treatment Of Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that data from its Phase 1